From evidence to action

At ICARS, our mission is to partner with Low- and Middle-income countries (LMICs) in their efforts to reduce drug-resistant infections.

We do this by co-developing tailored solutions with LMIC governments and researchers, who then implement them on the ground using ICARS funding and expertise, building on AMR National Action Plans.

Follow us and view our latest news

7. June 2024

ICARS Science Advisor Travels to China for RENOFARM Launch and Collaboration

6. June 2024

ICARS human health project marks a step forward in the mitigation of AMR in Georgia

ICARS – A Year in Review

ICARS is excited to share its key highlights and achievements in 2023 in the Year in Review report! In 2023, ICARS underwent significant organisational maturation, building upon the groundwork laid in preceding years. As our Executive Director took office, our expansion continued through collaborations with partners to implement and develop projects and activities, while also enhancing evidence generation to inform policy. We initiated new partnerships and strengthened existing ones nationally, regionally, and globally to advocate for country-owned antimicrobial resistance (AMR) solutions, alongside efforts to reinforce capacity and capabilities in Low- and Middle-Income Countries (LMICs). Additionally, we successfully attracted new donors to support our mission and activities. To learn more about ICARS’ highlights in 2023, read the document below.

Read more

ICARS Strategy 2022 – 2026

Guided by our vision of a world without drug-resistant infections, we have developed a new strategy with a revised outcome framework and refined the scope and goals of each of our interconnected pillars.

We are pleased to present a succinct overview of ICARS unique value proposition, followed by our overarching strategy that will run until 2026, as well as a roadmap that details our planned activities per pillar.

Read more

Join our mission

To achieve sustainable change in LMICs, we invite countries and foundations to join us as Strategic Funding Partners, Funding Partners or Mission Partners, in a truly international effort to mitigate antimicrobial resistance.

Please do not hesitate to contact our team for further information.

Find out more      Contact us